Drugs / 1XX BCMA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07340853 | Feb 2026 → May 2028 | plasma cell myeloma | Thomas Martin, MD | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1XX BCMA CAR-T cells | “Treatment with 1XX BCMA CAR-T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory multiple myeloma (RRMM).” NCT07340853 ↗ |
| Modality | Cell therapy | “Large numbers of the CAR-T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.” NCT07340853 ↗ |
| Route | Intravenous | “Given Intravenously (IV)” NCT07340853 ↗ |